Compared to single-specificity tracers, the dual-receptor targeting strategy enhances tumor targeting efficiency in NCI-H727 tumors and prolongs the tumor retention time, indicating that [68Ga]Ga-TATE-46 is a promising non-invasive tracer for detecting tumors that simultaneously express SSTR2and FAP (e.g., nasopharyngeal carcinoma, thyroid carcinoma and breast cancer), with good potential for clinical translation. This evidence concerns the gene FAP and breast cancer.